Clinical Trial Update: Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612 [Phase 3]

View source ↗

Summary

Phase 3 trial assessing persistence of antibodies after vaccination with meningococcal vaccine GSK134612 has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• GSK134612 (Meningococcal vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2019-08-06